Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to eight new employees under its 2024 Inducement Plan. The awards consist of time-based restricted stock units (RSUs) for 69,600 shares of common stock. The RSUs will vest in three equal installments on May 1 of 2026, 2027, and 2028, contingent on continued employment. These awards, approved by Intellia's compensation committee, were granted outside the company's stockholder-approved equity incentive plans in accordance with Nasdaq Listing Rule 5635(c)(4) as material inducement for employment.
Intellia Therapeutics (NASDAQ:NTLA), un'azienda in fase clinica specializzata in terapie basate su CRISPR, ha assegnato premi di incentivo a otto nuovi dipendenti nell'ambito del suo Piano di Incentivazione 2024. I premi consistono in unità azionarie vincolate (RSU) basate sul tempo, per un totale di 69.600 azioni ordinarie. Le RSU matureranno in tre tranche uguali il 1° maggio del 2026, 2027 e 2028, a condizione che l'impiego continui. Questi premi, approvati dal comitato per la remunerazione di Intellia, sono stati concessi al di fuori dei piani di incentivo azionario approvati dagli azionisti, in conformità con la regola di quotazione Nasdaq 5635(c)(4), come incentivo materiale per l'assunzione.
Intellia Therapeutics (NASDAQ:NTLA), una empresa en etapa clínica especializada en terapias basadas en CRISPR, ha otorgado premios de incentivo a ocho nuevos empleados bajo su Plan de Incentivos 2024. Los premios consisten en unidades de acciones restringidas (RSU) basadas en el tiempo por 69,600 acciones ordinarias. Las RSU se consolidarán en tres cuotas iguales el 1 de mayo de 2026, 2027 y 2028, condicionadas a la continuidad laboral. Estos premios, aprobados por el comité de compensación de Intellia, se concedieron fuera de los planes de incentivos accionarios aprobados por los accionistas, de acuerdo con la Regla de Listado Nasdaq 5635(c)(4) como un incentivo material para el empleo.
임상 단계의 유전자 편집 회사인 Intellia Therapeutics(NASDAQ:NTLA)는 2024년 유인 계획에 따라 8명의 신입 직원에게 유인 보상을 부여했습니다. 이 보상은 69,600주의 보통주에 대한 시간 기반 제한 주식 단위(RSU)로 구성됩니다. RSU는 2026년, 2027년, 2028년 5월 1일에 각각 3등분으로 베스팅되며, 계속 근무 조건이 충족되어야 합니다. 이 보상은 Intellia의 보상 위원회에서 승인되었으며, 나스닥 상장 규칙 5635(c)(4)에 따라 주주 승인 주식 인센티브 계획 외부에서 고용 유인을 위한 중요한 보상으로 부여되었습니다.
Intellia Therapeutics (NASDAQ:NTLA), une société en phase clinique spécialisée dans les thérapies basées sur CRISPR, a attribué des récompenses d'incitation à huit nouveaux employés dans le cadre de son Plan d'Incitation 2024. Ces récompenses consistent en des unités d'actions restreintes (RSU) basées sur le temps, représentant 69 600 actions ordinaires. Les RSU seront acquises en trois versements égaux les 1er mai 2026, 2027 et 2028, sous réserve de la poursuite de l'emploi. Ces récompenses, approuvées par le comité de rémunération d'Intellia, ont été accordées en dehors des plans d'incitation en actions approuvés par les actionnaires, conformément à la règle de cotation Nasdaq 5635(c)(4), comme incitation matérielle à l'emploi.
Intellia Therapeutics (NASDAQ:NTLA), ein klinisch tätiges Unternehmen für Genomeditierung mit Schwerpunkt auf CRISPR-basierten Therapien, hat acht neuen Mitarbeitern im Rahmen seines Inducement-Plans 2024 Anreizprämien gewährt. Die Prämien bestehen aus zeitbasierten Restricted Stock Units (RSUs) für 69.600 Stammaktien. Die RSUs werden in drei gleichen Raten am 1. Mai 2026, 2027 und 2028 fällig, vorbehaltlich einer fortgesetzten Beschäftigung. Diese Prämien, genehmigt vom Vergütungsausschuss von Intellia, wurden außerhalb der von den Aktionären genehmigten Aktienanreizpläne des Unternehmens gemäß der Nasdaq-Listing-Regel 5635(c)(4) als wesentliche Anreize für die Einstellung gewährt.
Positive
None.
Negative
None.
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an inducement grant to eight new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 69,600 shares of Intellia’s common stock, with one-third of such RSUs vesting on May 1, 2026, 2027 and 2028.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
